Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 27-33

  Olmos, D ^a,b   Arkenau, H T ^a   Ang, J E ^a   Ledaki, I ^b   Attard, G ^a,b   Carden, C P ^a   Reid, A H M ^a,b   A'Hern, R ^b   Fong, P C ^a,b   Oomen, N B ^a   Molife, R ^a   Dearnaley, D ^a   Parker, C ^a   Terstappen, L W M M ^c   de Bono, Johann S ^a,b,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Immunicon Corporation   (United States)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Castration resistant prostate cancer; Circulating tumour cell

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; MITOXANTRONE;

ADULT; AGED; ARTICLE; CANCER CELL; CASTRATION; CELL COUNT; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT FAILURE;

EID: 58949088650     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn544     Document Type: Article

References (19)

1. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
2. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
3. Scher HI, Morris MJ, Kelly WK et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005; 11: 5223-5232.
4. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 1996; 88: 1623-1634.
5. Collette L, Burzykowski T, Carroll K et al. Is prostate specific antigen a valid surrogate end-point for survival in hormonally treated patients with metastatic prostate cancer. J Clin Oncol 2005; 23: 6139-6148.
6. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2008; 450: 1235-1239.
7. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
8. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med 2004; 351: 781-791.
9. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
10. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-4224.
11. Cohen S, Punt C, Ianott N et al. Relationship of circulating tumour cells to tumour response, progression free survival and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
12. Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-718.
13. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409.
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern-Cooperative-Oncology-Group. Am J Clin Oncol 1982; 5: 649-655.
15. de Bono JS, Scher H, Montgomery B et al. Circulating tumor cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC). Clin Can Res 2008; In press.
16. Royston P. Explained variation for survival models. Stata J 2006; 6: 83-96.
17. Pachmann K, Camara O, Kavallaris A et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26: 1208-1215.
18. Fizazi K, Morat L, Chauveinc L et al. High detection of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007; 18: 518-521.
19. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058.